MGMT promoter methylation associated with improved survival for patients with WHO Grade II Gliomas
Further exploration into the endpoints of the NRG Oncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide ...
Jul 5, 2018
0
0